3H-咪唑并[4,5-b]吡啶-7-腈 | 78316-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 3H-咪唑并[4,5-b]吡啶-7-腈
• 英文名称: 3H-Imidazo[4,5-B]pyridine-7-carbonitrile
• 英文别名: 1H-imidazo[4,5-b]pyridine-7-carbonitrile
• CAS: 78316-13-9
• 化学式: C₇H₄N₄
• mdl: MFCD05723322
• 分子量: 144.13
• InChiKey: PSYSLTIGGKLQGF-UHFFFAOYSA-N

物化性质

• 沸点：
  228.8±50.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• NOVEL HETEROCYCLIC COMPOUND
  申请人：DAEWOONG PHARMACEUTICAL CO., LTD.

  公开号：US20170088551A1

  公开（公告）日：2017-03-30

  The present invention relates to a compound represented by chemical formula 1, which can be used for the prevention and treatment of diseases caused by abnormality in a prolyl-tRNA synthetase (PRS) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.

  本发明涉及一种化学式1所代表的化合物，可用于预防和治疗由脯氨酰-tRNA合成酶（PRS）活性异常引起的疾病，或其药用盐，以及制备该化合物的方法和包含该化合物的药物组合物。
• Heterocyclic compound
  申请人：Daewoong Pharmaceutical Co., Ltd.

  公开号：US10081634B2

  公开（公告）日：2018-09-25

  The present invention relates to a compound represented by chemical formula 1, which can be used for the prevention and treatment of diseases caused by abnormality in a prolyl-tRNA synthetase (PRS) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.

  本发明涉及一种化学式 1 所代表的可用于预防和治疗由脯氨酰-tRNA 合成酶（PRS）活性异常引起的疾病的化合物或其药学上可接受的盐、制备方法以及包含该化合物的药物组合物。
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
  申请人：Cytokinetics, Incorporated

  公开号：EP2139478A1

  公开（公告）日：2010-01-06
• FACTOR IXa INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170027916A1

  公开（公告）日：2017-02-02

  In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
• US9808445B2
  申请人：——

  公开号：US9808445B2

  公开（公告）日：2017-11-07